Reata Pharmaceuticals, Inc. to Report Second Quarter 2021 Financial Results and Provide an Update on Development Programs on August 9, 2021
Reata Pharmaceuticals (Nasdaq: RETA) will report its financial results and update on development programs after market close on August 9, 2021. A conference call will follow at 4:30 pm ET, accessible domestically at (866) 270-1533 and internationally at (412) 317-0797, using access code 10157197. Reata focuses on developing therapeutics targeting crucial molecular pathways for serious diseases, with investigational drugs bardoxolone methyl and omaveloxolone aiming to reduce inflammation and oxidative stress. Further details will be available on their investor website.
- Reata is developing novel therapeutics targeting serious diseases.
- Bardoxolone methyl and omaveloxolone target key pathways in cellular metabolism and inflammation.
- Bardoxolone and omaveloxolone are investigational drugs, with unestablished safety and efficacy.
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs after the market closes on August 9, 2021.
Reata’s management will host a conference call on August 9, 2021, at 4:30 pm ET. The conference call will be accessible by dialing (866) 270-1533 (toll-free domestic) or (412) 317-0797 (international) using the access code: 10157197. The webcast link is https://event.on24.com/wcc/r/3196578/57A5A4A99C3D3BA0F2D6A7D9D86B06B7.
Second quarter financial results to be discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call at https://www.reatapharma.com/investors/ and will be available for 12 months after the call. The audio recording and webcast will be accessible for at least 90 days after the event at https://www.reatapharma.com/investors/.
About Reata Pharmaceuticals, Inc.
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism, inflammation, and the cellular response to injury. Reata’s two most advanced clinical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. We possess exclusive, worldwide rights to develop, manufacture, and commercialize bardoxolone, omaveloxolone, and our next-generation Nrf2 activators, excluding certain Asian markets for bardoxolone in certain indications, which are licensed to Kyowa Kirin Co., Ltd. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005132/en/
FAQ
When will Reata Pharmaceuticals report its earnings?
What time is the Reata Pharmaceuticals conference call?
How can I access the Reata Pharmaceuticals earnings call?
What is the focus of Reata Pharmaceuticals?
What are bardoxolone and omaveloxolone?
